SOR-C13 emerges as a paradigm-shifting therapeutic solution against multifarious cancer phenotypes. Employing an ingenious mechanism, this potent compound efficaciously obstructs the nefarious SORCIN protein, thereby orchestrating a comprehensive blockade on the pernicious proliferation and dissemination of malignant tumors. Exuding its benevolence, SOR-C13 illumines a path of sanguine expectations for those afflicted with lung, breast, prostate, and ovarian cancer, heralding a captivating era of tailor-made therapeutic interventions in the intricate realm of oncology.
CAT No: R2062
CAS No: 1187852-48-7
Synonyms/Alias: SOR-C13;UNII-C79B5A73C4;1187852-48-7;C79B5A73C4;L-Arginine, L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-leucyl-L-histidyl-L-prolyl-L-seryl-L-lysyl-L-valyl-L-alpha-aspartyl-L-leucyl-L-prolyl-;(4S)-5-(((1S)-2-(((1S)-1-(((1S)-2-((2S)-2-(((1S)-2-(((1S)-5-Amino-1-(((1S)-1-(((1S)-1-(((1S)-1-((2S)-2-(((1S)-1-carboxy-4-guanidino-butyl)carbamoyl)pyrrolidine-1-carbonyl)-3-methyl-butyl)carbamoyl)-3-hydroxy-3-oxo-propyl)carbamoyl)-2-methyl-propyl)ca;L-ARGININE, L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LEUCYL-L-HISTIDYL-L-PROLYL-L-SERYL-L-LYSYL-L-VALYL-L-.ALPHA.-ASPARTYL-L-LEUCYL-L-PROLYL-;CHEMBL4228250;GTPL12562;BDBM50459973;DB15366;DA-58010;TRPV6 Calcium Channel Inhibitor SOR-C13;Q27895873;H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH;
Chemical Name: (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C72H116N20O19 |
M.W/Mr. | 1565.8 |
Sequence | One Letter Code:KEFLHPSKVDLPR Three Letter Code:H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH |
InChI | InChI=1S/C72H116N20O19/c1-39(2)31-48(84-63(102)49(33-42-17-8-7-9-18-42)85-60(99)46(24-25-56(94)95)81-59(98)44(75)19-10-12-26-73)62(101)88-52(34-43-36-78-38-80-43)70(109)92-30-16-23-55(92)67(106)89-53(37-93)65(104)82-45(20-11-13-27-74)61(100)90-58(41(5)6)68(107)86-50(35-57(96)97)64(103)87-51(32-40(3)4)69(108)91-29-15-22-54(91)66(105)83-47(71(110)111)21-14-28-79-72(76)77/h7-9,17-18,36,38-41,44-55,58,93H,10-16,19-35,37,73-75H2,1-6H3,(H,78,80)(H,81,98)(H,82,104)(H,83,105)(H,84,102)(H,85,99)(H,86,107)(H,87,103)(H,88,101)(H,89,106)(H,90,100)(H,94,95)(H,96,97)(H,110,111)(H4,76,77,79)/t44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-/m0/s1 |
InChI Key | LGANPTNILMNMES-TVNHODDRSA-N |
Canonical SMILES | CC(C)CC(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)N3CCCC3C(=O)NC(CCCN=C(N)N)C(=O)O)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)N |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N |
1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com